Table 3.
Epi | NE | Glucose | NEFA | Glycerol | BHB | CHOoxi | Fatoxi | |
---|---|---|---|---|---|---|---|---|
WALKING | ||||||||
Epi | −0.033 | −0.010 | +0.180 | +0.149 | +0.383 | +0.286 | +0.137 | |
NE | +0.197 | +0.079 | +0.294 | +0.399 | −0.003 | +0.299 | +0.436 | |
Glucose | +0.180 | +0.206 | +0.008 | +0.138 | +0.264 | +0.042 | +0.326 | |
NEFA | +0.256 | +0.251 | +0.068 | +0.856* | +0.425 | +0.485 | +0.638* | |
Glycerol | +0.333 | +0.568* | +0.086 | +0.892* | +0.468 | +0.581 | +0.722* | |
BHB | +0.533* | +0.085 | +0.131 | +0.493 | +0.343 | +0.335 | +0.445 | |
CHOoxi | +0.301 | +0.736* | +0.053 | +0.487 | +0.766* | +0.379 | +0.773* | |
Fatoxi | +0.155 | +0.620* | +0.097 | +0.695* | +0.836* | +0.212 | +0.747* | |
RUNNING | ||||||||
Epi | +0.305 | −0.111 | +0.158 | +0.392 | +0.054 | +0.476 | +0.293 | |
NE | +0.444 | +0.196 | +0.007 | +0.440 | −0.141 | +0.698* | +0.496 | |
Glucose | +0.165 | +0.532* | −0.068 | +0.021 | −0.312 | +0.232 | +0.217 | |
NEFA | +0.387 | +0.428 | +0.258 | +0.746* | +0.843* | +0.256 | +0.586* | |
Glycerol | +0.447 | +0.617* | +0.371 | +0.780* | +0.645* | +0.604* | +0.761* | |
BHB | +0.208 | −0.003 | −0.153 | +0.687* | +0.489 | +0.101 | +0.492 | |
CHOoxi | +0.591* | +0.794* | +0.542* | +0.486 | +0.609* | −0.005 | +0.530* | |
Fatoxi | +0.241 | +0.528* | +0.211 | +0.653* | +0.677* | +0.391 | +0.400 |
Upper and lower sections represent Cold and Neutral trials respectively for both Walking and Running. Epi, Epinephrine; NE, Norepinephrine; glucose; NEFA; non-esterified fatty acids; glycerol; BHB, beta-hydroxybutyrate; CHOoxi (carbohydrate oxidation), and fatoxi (fat oxidation).
Significantly correlated at p < 0.01.